X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3610) 3610
Publication (601) 601
Book Review (54) 54
Book Chapter (40) 40
Dissertation (18) 18
Conference Proceeding (5) 5
Book / eBook (2) 2
Magazine Article (2) 2
Newsletter (2) 2
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2202) 2202
index medicus (1763) 1763
microsatellite instability (1542) 1542
mismatch repair (1401) 1401
oncology (1270) 1270
mutation (1244) 1244
cancer (1036) 1036
dna mismatch repair (1026) 1026
female (978) 978
dna repair (952) 952
colorectal cancer (871) 871
male (814) 814
tumors (759) 759
genetic aspects (730) 730
animals (704) 704
middle aged (658) 658
genetics & heredity (657) 657
research (591) 591
aged (537) 537
colorectal neoplasms - genetics (531) 531
adult (525) 525
dna (520) 520
immunohistochemistry (515) 515
mice (486) 486
mutl protein homolog 1 (475) 475
mismatch repair deficiency (471) 471
colon-cancer (460) 460
deoxyribonucleic acid--dna (454) 454
colorectal neoplasms, hereditary nonpolyposis - genetics (451) 451
mutations (438) 438
digestive system diseases (435) 435
proteins (427) 427
colorectal-cancer (422) 422
biochemistry & molecular biology (419) 419
nonpolyposis colorectal-cancer (416) 416
lynch syndrome (411) 411
genes (399) 399
dna-binding proteins - genetics (393) 393
dna damage (368) 368
pathology (365) 365
base pair mismatch (357) 357
analysis (351) 351
expression (330) 330
cell biology (325) 325
dna methylation (319) 319
genetics (318) 318
dna mismatch repair - genetics (310) 310
gene mutations (307) 307
phenotype (306) 306
article (303) 303
congenital, hereditary, and neonatal diseases and abnormalities (300) 300
multidisciplinary sciences (298) 298
lynch-syndrome (296) 296
chemotherapy (291) 291
dna repair - genetics (284) 284
prognosis (279) 279
research article (272) 272
aged, 80 and over (261) 261
gene (261) 261
gene expression (258) 258
nuclear proteins - genetics (256) 256
neoplasms (252) 252
colorectal neoplasms - pathology (251) 251
health aspects (248) 248
muts homolog 2 protein - genetics (244) 244
adaptor proteins, signal transducing (242) 242
apoptosis (237) 237
carcinoma (235) 235
medicine (230) 230
colorectal carcinoma (227) 227
genomes (223) 223
genetic predisposition to disease (222) 222
immunotherapy (222) 222
base sequence (220) 220
methylation (215) 215
care and treatment (207) 207
msh2 (207) 207
genomic instability (206) 206
muts homolog 2 protein (205) 205
endometrial cancer (204) 204
mlh1 (201) 201
neoplasm proteins - genetics (200) 200
risk (200) 200
survival (197) 197
hmlh1 (196) 196
gastroenterology & hepatology (195) 195
microsatellite repeats (194) 194
patients (194) 194
polymerase chain reaction (193) 193
repair (193) 193
carrier proteins (191) 191
risk factors (191) 191
adaptor proteins, signal transducing - genetics (187) 187
cell line, tumor (187) 187
genomics (186) 186
diagnosis (185) 185
germ-line mutation (185) 185
nuclear proteins (184) 184
proto-oncogene proteins - genetics (184) 184
biology (183) 183
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3603) 3603
French (19) 19
German (16) 16
Chinese (7) 7
Russian (5) 5
Japanese (4) 4
Korean (3) 3
Spanish (3) 3
Bulgarian (1) 1
Hungarian (1) 1
Norwegian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 06/2015, Volume 372, Issue 26, pp. 2509 - 2520
Persons with mismatch repair–deficient tumors are more likely than persons with mismatch repair–proficient tumors to benefit from pembrolizumab — which... 
MEDICINE, GENERAL & INTERNAL | COLORECTAL CARCINOMAS | ANTI-PD-L1 ANTIBODY | SAFETY | MICROSATELLITE INSTABILITY | DNA | GERMLINE MUTATIONS | PREDISPOSE | CLINICAL ACTIVITY | CANCER | LYMPHOCYTES | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Colorectal Neoplasms - genetics | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Disease-Free Survival | Neoplasm Metastasis - genetics | Neoplasm Metastasis - drug therapy | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | DNA Mismatch Repair | Adult | Female | Adenocarcinoma - genetics | Aged | Colorectal Neoplasms - pathology | Antibody diversity | Carcinoma | Genetic disorders | Analysis | Research | Risk factors | Cancer | Tumors | Antigens | Yeast | PD-1 protein | Colorectal carcinoma | Body weight | Colorectal cancer | Autoantigens | DNA repair | Survival | Metastases | Pembrolizumab | Immune checkpoint | Immunogenicity | Mismatch repair | Death | Mutation | Genetic recombination | Cancer therapies | Drug dosages | Immune system | Medical research | Melanoma | Patients | Studies | Hypotheses | Pancreatic cancer | Epigenetics | Biomarkers | Ligands
Journal Article
Science, ISSN 0036-8075, 07/2017, Volume 357, Issue 6349, pp. 409 - 413
The genomes of cancers deficient in mismatch repair contain exceptionally high numbers of somatic mutations. In a proof-of-concept study, we previously showed... 
CELL LUNG-CANCER | SURVIVAL | COLORECTAL CARCINOMAS | RECEIVING NIVOLUMAB | IMMUNOTHERAPY | MICROSATELLITE INSTABILITY | MULTIDISCIPLINARY SCIENCES | LONG-TERM SAFETY | NEOANTIGENS | CHECKPOINT BLOCKADE | LYMPHOCYTES | Neoplastic Syndromes, Hereditary - immunology | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Neoplastic Syndromes, Hereditary - mortality | Young Adult | Colorectal Neoplasms - therapy | Brain Neoplasms - immunology | DNA Mismatch Repair | Aged, 80 and over | Adult | Female | Neoplastic Syndromes, Hereditary - genetics | Brain Neoplasms - mortality | Biomarkers, Tumor - antagonists & inhibitors | Colorectal Neoplasms - mortality | Antibodies, Monoclonal, Humanized - therapeutic use | Antigens, Neoplasm - immunology | Brain Neoplasms - genetics | Disease-Free Survival | Colorectal Neoplasms - immunology | Cell Cycle Checkpoints - drug effects | Brain Neoplasms - therapy | Neoplastic Syndromes, Hereditary - therapy | T-Lymphocytes - immunology | Aged | Mutation | Programmed Cell Death 1 Receptor - immunology | Colorectal cancer | Genetic aspects | Nucleotide sequencing | Health aspects | DNA repair | Methods | Tumors | DNA sequencing | Yeast | PD-1 protein | Antibodies | Clinical trials | Genomes | Functional analysis | Lymphocytes T | Patients | Survival | Colon cancer | Immune checkpoint | Immunotherapy | Mismatch repair | Pancreatic cancer | Biomarkers | Bioindicators | Colon | Solid tumors | Genetic recombination | Repair | Cancer | Apoptosis
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2015, Volume 373, Issue 20, pp. 1979 - 1979
Journal Article
The Oncologist, ISSN 1083-7159, 10/2016, Volume 21, Issue 10, pp. 1200 - 1211
Journal Article
MODERN PATHOLOGY, ISSN 0893-3952, 07/2019, Volume 32, Issue 7, pp. 977 - 987
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 147, Issue 6, pp. 1308 - 1316.e1
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2013, Volume 50, Issue 5, pp. 987 - 996
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 146, Issue 3, pp. 643 - 646.e8
Journal Article